Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p18AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | T cell | Survival | ||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | adult T cell leukemia |
| ICD-0-3 | NA |
| Methods | qPCR, Luciferase reporter assay, RIP, other |
| Sample | ATL tissues and T-cell lines (MT-2, MT4, C8166, MT-1, HPB-ATL-2, HPB-ATL-T,410 ED, and TL-Om1) |
| Expression Pattern | up-regulated |
| Function Description | E2F1 induced ANRIL transcription by enhancing its promoter activity. Knockdown of ANRIL in ATL cells repressed cellular proliferation and increased apoptosis in vitro and in vivo As a mechanism for these actions, we found that ANRIL targeted EZH2 and activated the NF-?B pathway in ATL cells. This activation was independent of the histone methyltransferase (HMT) activity of EZH2 but required the formation of an ANRIL/EZH2/p65 ternary complex. A chromatin immunoprecipitation assay revealed that ANRIL/EZH2 enhanced p65 DNA binding capability. In addition, we observed that the ANRIL/EZH2 complex repressed p21/CDKN1A transcription through H3K27 trimethylation of the p21/CDKN1A promoter. |
| Pubmed ID | 30258009 |
| Year | 2018 |
| Title | Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells Through Cooperation With EZH2 |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for adult T cell leukemia | OMIM COSMIC |